Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company Announce Initiation of a Phase I Clinical Trial of Brentuximab Vedotin in Combination with Chemotherapy for Front-line Systemic ALCL

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed systemic anaplastic large cell lymphoma (ALCL) patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, which is highly expressed in ALCL.